Share on

Middle East and Africa Breast Biopsy Market Research Report - Segmented By Type, Product, Guidance & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Trends, COVID-19 Impact and Growth Forecast (2024 to 2029)

Published: March, 2023
ID: 4108
Pages: 130
Formats: report pdf report excel report power bi report ppt

MEA Breast Biopsy Market Size (2024 to 2029)

As per the research report, the Middle East and Africa Breast Biopsy Market size are valued at USD 39.48 million in 2024. It is forecasted to be growing at a CAGR of 10.7% and worth USD 65.64 million by 2029.

Liquid biopsy is a blood test that helps physicians find cancer cells or tumor DNA fragments in the blood. This approach avoids the need for surgical and needle biopsies and aids clinicians in detecting cancer in its early stages. Various players are undertaking clinical trials to show the efficacy and efficiency of liquid biopsy in oncology; the good results are expected to open new opportunities for market players. The introduction of highly improved and minimally invasive breast biopsy equipment is projected to open up significant market opportunities. Furthermore, new technologies are expected to develop in the near future and an increase in the utilization of mammography-guided stereotactic biopsy. It is expected that diseases such as cancer would grow more frequently in the Middle East in the coming years. The number of cancer cases is predicted to increase by twice as fast in the coming decade.

The rapid expansion of the Middle East and Africa market during the forecast period is due to new product approvals and launches and a growing preference for minimally invasive and image-guided needle biopsies such as vacuum-assisted biopsy and core needle biopsy. Breast cancer incidence is on the rise; women are becoming more aware of breast cancer screening programs as they get older, especially around the age of 40 and after menopause. The fastest growth of breast cancer in this nation has increased investments and government money for research and development in many fields. Despite having no evidence of breast cancer, many women have been observed to undergo this operation to eliminate any danger of breast cancer. As a result, there is a clear market demand among patients receiving these surgeries as a preventive step for protection against any form of breast cancer that is vulnerable.

Because biopsy needles are reused, the risk of infection during these operations is increased. However, uncertain regulatory issues, infection risks associated with breast biopsy procedures, and confusing reimbursement practices limit the market growth. The market's growth is also expected to be hampered by a lack of information about novel breast biopsy techniques and the danger of infection associated with the operations. In addition, trained surgeons who can undertake minimally invasive biopsy techniques are in short supply.

This research report on the Middle East and Africa breast biopsy market has been segmented and sub-segmented into the following categories:

By Type: 

  • Open Surgical Breast Biopsy
  • Needle Breast Biopsy

By Product: 

  • Biopsy Tables
  • Localization Wires
  • Biopsy Needles
  • Guidance Systems
  • Others

By Guidance: 

  • MRI-Guided Breast Biopsy
  • Mammography-Guided Stereotactic Breast Biopsy
  • Ultrasound-Guided Breast Biopsy
  • Other Techniques

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

KEY MARKET PLAYERS:

Geographically, the MEA region is expected to account for a small portion of the global breast biopsy market share during the forecast period, yet, expected to be growing at a healthy growth rate. The rising number of young people being influenced by smoke, obesity, the prevalence of diseases such as hepatitis C, and industrial and agricultural pollutants are contributing to the market growth in the Middle East and Africa. Breast cancer has a high incidence and mortality rate, which means there is a big unmet need for breast cancer diagnostics. The need for mammography is predicted to rise as the number of incidences and cases of death rises. This is projected to continue to be a primary driver for the market over the forecast period.

KEY MARKET PLAYERS:

Companies that are playing a notable role in the MEA breast biopsy market profiled in the report are Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample